MRTX849 + Cetuximab for Colorectal Cancer
Recruiting at 991 trial locations
MT
Overseen ByMirati Therapeutics Study Locator Services
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Mirati Therapeutics Inc.
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
This trial is for adults with advanced colorectal cancer who have the KRAS G12C mutation. They must have had one prior treatment with specific chemotherapy and shown disease progression afterwards. People can't join if they've had brain metastases, previous treatments targeting KRAS G12C, or anti-EGFR antibody therapies.Inclusion Criteria
My colorectal cancer has a specific KRAS G12C mutation.
My advanced colorectal cancer progressed after first-line chemotherapy.
Exclusion Criteria
I have been treated with an anti-EGFR antibody before.
I have been treated with a drug targeting the KRAS G12C mutation.
I have active cancer spread to my brain.
Treatment Details
Interventions
- Cetuximab (Monoclonal Antibodies)
- FOLFIRI Regimen (Small Molecule)
- mFOLFOX6 Regimen (Small Molecule)
- MRTX849 (Small Molecule)
Trial OverviewThe study compares MRTX849 combined with cetuximab to standard chemotherapies (mFOLFOX6 or FOLFIRI) in second-line treatment of colorectal cancer with a specific mutation. It's an open-label trial where patients are randomly assigned to either the new drug combo or standard chemo.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: MRTX849 + CetuximabExperimental Treatment2 Interventions
Group II: mFOLFOX6 or FOLFIRIActive Control2 Interventions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mirati Therapeutics Inc.
Lead Sponsor
Trials
73
Recruited
8,900+
Dr. Charles M. Baum
Mirati Therapeutics Inc.
Chief Executive Officer since 2023
MD, PhD
Dr. Joseph Leveque
Mirati Therapeutics Inc.
Chief Medical Officer since 2021
MD